SCSharon Chiang

Sharon Chiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sharon Chiang has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Best Practice Guidelines for Bioethical Use of Medical AI in Healthcare. An eDelphi Consensus Exercise

    by Ramón J. Palmer-Coll, Verónica A. Brokke, Miguel Cortijo-Martinez, Sharon Chiang, María Soledad Paladino, Constantine Psimopoulos, Sandeep Reddy, Jason T. Eberl, Thomas Ploug, Andrzej Grzybowski, et al.

    Introduction: Medical Artificial Intelligence (MAI) is transforming healthcare but raises significant ethical concerns. Despite emerging principles and regulations, to our knowledge, no standardized clinical bioethics framework exists to guide MAI practice. Objective: This Delphi study sought global expert agreement on ethical challenges, principles, guidelines, and practical tools for MAI use. Method: A four-round international eDelphi study, conducted under ACCORD and DELPHISTAR guidance, engaged multidisciplinary stakeholders identified through systematic review and targeted recruitment. Preliminary items were evidence-derived and iteratively refined. Consensus (≥ 80% agreement across two rounds) was predefined. Surveys were anonymized and randomized. Ethical approval and protocol registration were secured before study initiation. Results: The panel included 53 participants from 21 countries. Survey rounds started November 2025 and ended February 2026. 170 items were considered. 132 reached consensus. Items were classified into bioethical issues, values, principles, solutions, a checklist for clinicians, and report markers for risk management. Discussion: This study produced clinician-focused practice guidelines for the bioethical use of MAI. Ethical components aligned with prior literature, while no new bioethical principles met consensus. Limitations included geographic imbalance and stakeholder representation. Recommendations emphasized human responsibility, governance, and practical implementation tools. Conclusion: This Delphi consensus provides practical, ethics-based guidance for the responsible integration of MAI into clinical practice and institutional governance.

  • Integrating longitudinal seizure, medication, and quality of life data into epilepsy eare: A randomized crossover study of an Epic-integrated dashboard

    by Sharon Chiang, Nicolette Miller, Emerald Wan, Robert Moss, Nilika S. Singhal, Jennifer A. Pearce, Danilo Bernardo, Susannah Cornes, Joline M. Fan, Paul A. Garcia, et al.

  • Open Access

    Spyglass: a framework for reproducible and shareable neuroscience research

    by Kyu Hyun Lee, Eric L Denovellis, Ryan Ly, Jeremy Magland, Jeff Soules, Alison E Comrie, Daniel P Gramling, Jennifer A Guidera, Rhino Nevers, Philip Adenekan, et al.

    Scientific progress depends on reliable and reproducible results. Progress can be accelerated when data are shared and re-analyzed to address new questions. Current approaches to storing and analyzing neural data involve bespoke formats and software that make replication and reuse of data difficult. To address these challenges, we created Spyglass, an open-source data management and analysis framework written in Python. Spyglass provides reproducible pipelines for common neuroscience analyses and sharing of raw data, intermediate analyses, and final results within and across labs. Spyglass uses the Neurodata Without Borders (NWB) standard and includes pipelines for spectral filtering, spike sorting, pose tracking, and neural decoding. Spyglass can be extended to apply existing and newly developed pipelines to datasets from multiple sources. We demonstrate these features in the context of a cross-laboratory replication by applying advanced state space decoding algorithms to publicly available data. New users can try out Spyglass on a Jupyter Hub hosted by HHMI and 2i2c: https://spyglass.hhmi.2i2c.cloud/.

  • Open Access

    Benzodiazepine rescue medication administration for seizure clusters: Real‐world retrospective outcomes

    by Sharon Chiang, Robert Moss, Sunita N. Misra, Enrique Carrazana, Adrian L. Rabinowicz

    Objective: Benzodiazepine rescue medications are established as therapy for acute termination of seizure clusters. A post‐hoc analysis of a clinical trial of seizure cluster treatment with diazepam nasal spray found a potential longer‐term impact over a year of treatment. In this retrospective analysis, we tested the hypothesis that benzodiazepine‐treated seizure clusters are associated with prolonged time to the next seizure cluster compared with untreated seizure clusters in a patient‐reported real‐world database.Methods: We analyzed data on self‐reported seizures and benzodiazepine rescue medication administration in the Seizure Tracker™ database between 2007 and 2022. Kaplan–Meier analysis was used to compare treated vs untreated seizure clusters with respect to time to start of the next seizure cluster or immediate‐use medication administration. Mixed‐effects analysis was used to compare the number of seizures per cluster for treated and untreated seizure clusters. Robustness of findings was evaluated across three operational seizure‐cluster definitions: ≥2 seizures in 4 hours as primary analysis and in 6 and 24 hours as sensitivity analyses.Results: A total of 10 889 benzodiazepine immediate‐use medication administrations (n = 220 patients) met inclusion criteria. Benzodiazepine rescue administrations were followed by longer time to the next seizure cluster or rescue administration, compared with untreated seizure clusters, corresponding to a median of 4.9 days following treated seizure clusters and a median of 0.8 days following untreated seizure clusters. This prolongation was driven by a minority of patients (accounting for 45.9% of seizure clusters in the sample) and patients were more likely to be women. The number of seizures per cluster was lower when treatment was administered earlier in the seizure cluster.Significance: These retrospective real‐world data suggest that the effect of benzodiazepines on termination of seizure clusters may be more pronounced when administration occurs earlier after onset, and support a hypothesis of a possible longer‐term effect of benzodiazepines beyond immediate‐use acute seizure termination.


  • Open Access

    Association of reductions in rescue medication requirements with vagus nerve stimulation: Results of long-term community collected data from a seizure diary app

    by Cameron P. Beaudreault, Sharon Chiang, Ariel Sacknovitz, Robert Moss, Paige Brabant, David Zuckerman, Jessica R. Dorilio, Eris Spirollari, Alexandria F. Naftchi, Patricia E. McGoldrick, et al.


  • Open Access

    State-dependent effects of responsive neurostimulation depend on seizure localization

    by Sharon Chiang, Ankit N Khambhati, Thomas K Tcheng, Audra Plenys Loftman, Nicholas R Hasulak, Emily A Mirro, Martha J Morrell, Vikram R Rao

    Brain-responsive neurostimulation (RNS) is firmly ensconced among treatment options for drug-resistant focal epilepsy, but over a quarter of patients treated with the RNS® System do not experience meaningful seizure reduction. Initial titration of RNS therapy is typically similar for all patients, raising the possibility that treatment response might be enhanced by consideration of patient-specific variables. Indeed, small, single-centre studies have yielded preliminary evidence that RNS System effectiveness depends on the brain state during which stimulation is applied. The generalizability of these findings remains unclear, however, and it is unknown whether state-dependent effects of responsive neurostimulation are also stratified by location of the seizure onset zone where stimulation is delivered. We aimed to determine whether state-dependent effects of the RNS System are evident in the large, diverse, multi-centre cohort of RNS System clinical trial participants and to test whether these effects differ between mesiotemporal and neocortical epilepsies. Eighty-one of 256 patients treated with the RNS System across 31 centres during clinical trials met the criteria for inclusion in this retrospective study. Risk states were defined in relation to phases of daily and multi-day cycles of interictal epileptiform activity that are thought to determine seizure likelihood. We found that the probabilities of risk state transitions depended on the stimulation parameter being changed, the starting seizure risk state and the stimulated brain region. Changes in two commonly adjusted stimulation parameters, charge density and stimulation frequency, produced opposite effects on risk state transitions depending on seizure localization. Greater variance in acute risk state transitions was explained by state-dependent responsive neurostimulation for bipolar stimulation in neocortical epilepsies and for monopolar stimulation in mesiotemporal epilepsies. Variability in the effectiveness of RNS System therapy across individuals may relate, at least partly, to the fact that current treatment paradigms do not account fully for fluctuations in brain states or locations of simulation sites. State-dependence of electrical brain stimulation may inform the development of next-generation closed-loop devices that can detect changes in brain state and deliver adaptive, localization-specific patterns of stimulation to maximize therapeutic effects.


  • Open Access

    Spyglass: a framework for reproducible and shareable neuroscience research

    by Kyu Hyun Lee, Eric L. Denovellis, Ryan Ly, Jeremy Magland, Jeff Soules, Alison E. Comrie, Daniel P. Gramling, Jennifer A. Guidera, Rhino Nevers, Philip Adenekan, et al.

    Scientific progress depends on reliable and reproducible results. Progress can be accelerated when data are shared and re-analyzed to address new questions. Current approaches to storing and analyzing neural data involve bespoke formats and software that make replication and reuse of data difficult. To address these challenges, we created Spyglass, an open-source data management and analysis framework written in Python. Spyglass provides reproducible pipelines for common neuroscience analyses and sharing of raw data, intermediate analyses, and final results within and across labs. Spyglass uses the Neurodata Without Borders (NWB) standard and includes pipelines for spectral filtering, spike sorting, pose tracking, and neural decoding. Spyglass can be extended to apply existing and newly developed pipelines to datasets from multiple sources. We demonstrate these features in the context of a cross-laboratory replication by applying advanced state space decoding algorithms to publicly available data. New users can try out Spyglass on a Jupyter Hub hosted by HHMI and 2i2c: https://spyglass.hhmi.2i2c.cloud/ .


  • Four State Sleep Staging From a Multilayered Algorithm Using Electrocardiographic and Actigraphic Data

    by Mario Garingo, Chaim Katz, Kramay Patel, Stephan Meyer Zum Alten Borgloh, Parisa Sabetian, Jeffrey Durmer, Sharon Chiang, Vikram R. Rao, John M. Stern

    Purpose: Sleep studies are important to evaluate sleep and sleep-related disorders. The standard test for evaluating sleep is polysomnography, during which several physiological signals are recorded separately and simultaneously with specialized equipment that requires a technologist. Simpler recordings that can model the results of a polysomnography would provide the benefit of expanding the possibilities of sleep recordings. Methods: Using the publicly available sleep data set from the multiethnic study of atherosclerosis and 1769 nights of sleep, we extracted a distinct data subset with engineered features of the biomarkers collected by actigraphic, oxygenation, and electrocardiographic sensors. We then applied scalable models with recurrent neural network and Extreme Gradient Boosting (XGBoost) with a layered approach to produce an algorithm that we then validated with a separate data set of 177 nights. Results: The algorithm achieved an overall performance of 0.833 accuracy and 0.736 kappa in classifying into four states: wake, light sleep, deep sleep, and rapid eye movement (REM). Using feature analysis, we demonstrated that heart rate variability is the most salient feature, which is similar to prior reports. Conclusions: Our results demonstrate the potential benefit of a multilayered algorithm and achieved higher accuracy and kappa than previously described approaches for staging sleep. The results further the possibility of simple, wearable devices for sleep staging. Code is available at https://github.com/NovelaNeuro/nEureka-SleepStaging.

  • Open Access

    Spinal epidural arteriovenous fistula with nerve root enhancement mimicking myeloradiculitis: a case report

    by Sharon Chiang, Douglas B. Pet, Jason F. Talbott, Sara C. LaHue, Vanja C. Douglas, Nicole Rosendale

    Background: Gadolinium enhancement of spinal nerve roots on magnetic resonance imaging (MRI) has rarely been reported in spinal dural arteriovenous fistula (SDAVF). Nerve root enhancement and cerebrospinal fluid (CSF) pleocytosis can be deceptive and lead to a misdiagnosis of myeloradiculitis. We report a patient who was initially diagnosed with neurosarcoid myeloradiculitis due to spinal nerve root enhancement, mildly inflammatory cerebrospinal fluid, and pulmonary granulomas, who ultimately was found to have an extensive symptomatic SDAVF. Case presentation: A 52-year-old woman presented with a longitudinally extensive spinal cord lesion with associated gadolinium enhancement of the cord and cauda equina nerve roots, and mild lymphocytic pleocytosis. Pulmonary lymph node biopsy revealed non-caseating granulomas and neurosarcoid myeloradiculitis was suspected. She had rapid and profound clinical deterioration after a single dose of steroids. Further work-up with spinal angiography revealed a thoracic SDAVF, which was surgically ligated leading to clinical improvement. Conclusions: This case highlights an unexpected presentation of SDAVF with nerve root enhancement and concurrent pulmonary non-caseating granulomas, leading to an initial misdiagnosis with neurosarcoidosis. Nerve root enhancement has only rarely been described in cases of SDAVF; however, as this case highlights, it is an important consideration in the differential diagnosis of non-inflammatory causes of longitudinally extensive myeloradiculopathy with nerve root enhancement. This point is highly salient due to the importance of avoiding misdiagnosis of SDAVF, as interventions such as steroids or epidural injections used to treat inflammatory or infiltrative mimics may worsen symptoms in SDAVF. We review the presentation, diagnosis, and management of SDAVF as well as a proposed diagnostic approach to differentiating SDAVF from inflammatory myeloradiculitis.


  • Development of a core outcome set for quality of life for adults with drug‐resistant epilepsy: A multistakeholder Delphi consensus study

    by Sharon Chiang, Robert Moss, John M. Stern, Inna Hughes, S. Andrew Josephson, Jennifer R. Pearce, Brandon E. Kopald, Anup D. Patel, Vikram R. Rao

    Objective: In 2017, the American Academy of Neurology (AAN) convened the AAN Quality Measurement Set working group to define the improvement and maintenance of quality of life (QOL) as a key outcome measure in epilepsy clinical practice. A core outcome set (COS), defined as an accepted, standardized set of outcomes that should be minimally measured and reported in an area of health care research and practice, has not previously been defined for QOL in adult epilepsy.Methods: A cross‐sectional Delphi consensus study was employed to attain consensus from patients and caregivers on the QOL outcomes that should be minimally measured and reported in epilepsy clinical practice. Candidate items were compiled from QOL scales recommended by the AAN 2017 Quality Measurement Set. Inclusion criteria to participate in the Delphi study were adults with drug‐resistant epilepsy diagnosed by a physician, no prior diagnosis of psychogenic nonepileptic seizures or a cognitive and/or developmental disability, or caregivers of patients meeting these criteria.Results: A total of 109 people satisfied inclusion/exclusion criteria and took part in Delphi Round 1 (patients, n = 95, 87.2%; caregivers, n = 14, 12.8%), and 55 people from Round 1 completed Round 2 (patients, n = 43, 78.2%; caregivers, n = 12, 21.8%). One hundred three people took part in the final consensus round. Consensus was attained by patients/caregivers on a set of 36 outcomes that should minimally be included in the QOL COS. Of these, 32 of the 36 outcomes (88.8%) pertained to areas outside of seizure frequency and severity.Significance: Using patient‐centered Delphi methodology, this study defines the first COS for QOL measurement in clinical practice for adults with drug‐resistant epilepsy. This set highlights the diversity of factors beyond seizure frequency and severity that impact QOL in epilepsy.